RE: News From Conference17 May 2018 12:04
Frits,
you need to look for this:
PL52 PARALLEL SESSION
BREAKTHROUGH THERAPIES IN AUTOIMMUNE DISEASES 2
The Date Muller is speaking on P140 is:
19-May-2018 10:30 12:30
"In a multicenter, randomized, placebo-controlled phase-IIb study for lupus, P140/LupuzorTM was found to be safe and met its primary efficacy end points, confirming pre-clinical data generated in MRL/lpr lupus-prone mice. Lupuzor is currently evaluated in phase-III clinical trials in the US, Europe and Mauritius. We discovered that P140 targets autophagy, a finely orchestrated catabolic process, involved in the regulation of inflammation and in the biology of immune cells. P140 acts directly on a particular form of autophagy called chaperone-mediated autophagy, which is hyperactivated in lupus in certain subsets of lymphocytes. The �correcting� effect of P140 on autophagy results in a weaker signaling of autoreactive T cells, leading to a significant improvement of physiopathological status of treated mice.
Conclusion
These findings open novel avenues of therapeutic intervention in other pathological conditions in which reduction of autophagy activity would be desired. New data will be presented in the context of neurological autoinflammatory diseases.
Co-authors
S. Muller 1
1CNRS, UPR 3572- Institut de biologie mol�culaire et cellulaire IBMC, Strasbourg, France"